AIM: To determine the association between serum levels of growth-related gene product β (GROβ) and clinical parameters in esophageal squamous cell carcinoma (ESCC). METHODS: Using enzyme-linked immunosorbent assay, serum GROβ levels were measured in ESCC patients (n = 72) and healthy volunteers (n = 83). The association between serum levels of GROβ and clinical parameters of ESCC was analyzed statistically. RESULTS: The serum GROβ levels were much higher in ESCC patients than in healthy controls (median: 645 ng/L vs 269 ng/L, P < 0.05). Serum GROβ levels were correlated positively with tumor size, lymph node metastasis, and tumor-node-metastasis (TNM) staging, but not with gender or the histological grade of tumors in ESCC patients. The sensitivity and specificity of the assay for serum GROβ were 73.61% and 56.63%, respectively. CONCLUSION: GROβ may function as an oncogene product and contribute to tumorigenesis and metastasis of ESCC.
AIM: To determine the association between serum levels of growth-related gene product β (GROβ) and clinical parameters in esophageal squamous cell carcinoma (ESCC). METHODS: Using enzyme-linked immunosorbent assay, serum GROβ levels were measured in ESCC patients (n = 72) and healthy volunteers (n = 83). The association between serum levels of GROβ and clinical parameters of ESCC was analyzed statistically. RESULTS: The serum GROβ levels were much higher in ESCC patients than in healthy controls (median: 645 ng/L vs 269 ng/L, P < 0.05). Serum GROβ levels were correlated positively with tumor size, lymph node metastasis, and tumor-node-metastasis (TNM) staging, but not with gender or the histological grade of tumors in ESCC patients. The sensitivity and specificity of the assay for serum GROβ were 73.61% and 56.63%, respectively. CONCLUSION: GROβ may function as an oncogene product and contribute to tumorigenesis and metastasis of ESCC.
Authors: C Limatola; A M Mileo; A Giovannelli; F Vacca; M T Ciotti; D Mercanti; A Santoni; F Eusebi Journal: J Biol Chem Date: 1999-12-17 Impact factor: 5.157
Authors: K L Redmond; N T Crawford; H Farmer; Z C D'Costa; G J O'Brien; N E Buckley; R D Kennedy; P G Johnston; D P Harkin; P B Mullan Journal: Oncogene Date: 2010-03-29 Impact factor: 9.867
Authors: J A Belperio; M P Keane; D A Arenberg; C L Addison; J E Ehlert; M D Burdick; R M Strieter Journal: J Leukoc Biol Date: 2000-07 Impact factor: 4.962
Authors: H Kawaguchi; S Ohno; M Miyazaki; K Hashimoto; A Egashira; H Saeki; M Watanabe; K Sugimachi Journal: Cancer Date: 2000-10-01 Impact factor: 6.860
Authors: Yiting Li; Ricardo Flores; Alexander Yu; M Fatih Okcu; Jeffrey Murray; Murali Chintagumpala; John Hicks; Ching C Lau; Tsz-Kwong Man Journal: Cancer Date: 2010-08-30 Impact factor: 6.860
Authors: D Wang; W Yang; J Du; M N Devalaraja; P Liang; K Matsumoto; K Tsubakimoto; T Endo; A Richmond Journal: Oncogene Date: 2000-09-21 Impact factor: 9.867
Authors: Eman A Toraih; Manal S Fawzy; Abdullah I El-Falouji; Elham O Hamed; Nader A Nemr; Mohammad H Hussein; Noha M Abd El Fadeal Journal: Mol Med Date: 2016-09-12 Impact factor: 6.354